United Therapeutics Corporation (UTHR) Shares Gap Down After Insider Selling

United Therapeutics Corporation (NASDAQ:UTHR) shares gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $116.64, but opened at $120.82. United Therapeutics Corporation shares last traded at $120.66, with a volume of 354,822 shares traded.

Specifically, CEO Martine A. Rothblatt sold 1,232 shares of United Therapeutics Corporation stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the transaction, the chief executive officer now directly owns 2,301 shares in the company, valued at $306,769.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 580 shares of United Therapeutics Corporation stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the transaction, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,178 shares of company stock valued at $3,289,427. 7.80% of the stock is currently owned by company insiders.

A number of research analysts recently issued reports on the company. Jefferies Group LLC reiterated a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. UBS AG reiterated a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. BidaskClub upgraded United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $134.50.

The company has a 50 day moving average price of $129.84 and a 200-day moving average price of $130.28. The stock has a market cap of $5.36 billion, a price-to-earnings ratio of 14.31 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.42 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Comerica Bank lifted its position in shares of United Therapeutics Corporation by 1.3% during the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock worth $4,635,000 after purchasing an additional 458 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of United Therapeutics Corporation by 1.8% during the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock worth $16,583,000 after purchasing an additional 2,223 shares during the last quarter. Clarity Capital KCPS Ltd. bought a new position in shares of United Therapeutics Corporation during the first quarter worth about $230,000. State of Wisconsin Investment Board bought a new position in shares of United Therapeutics Corporation during the second quarter worth about $5,256,000. Finally, Argent Capital Management LLC lifted its position in shares of United Therapeutics Corporation by 2.4% during the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 60 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/2887560/united-therapeutics-corporation-uthr-shares-gap-down-after-insider-selling.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.